| CIDS | cellular immunity deficiency syndrome; circular intensity differential scattering; continuous insuli... |
|---|---|
| CMI | carbohydrate metabolism index; care management integration; case mix index; cell-mediated immunity; ... |
| HI | half-scan with interpolation; head injury; health insurance; hearing impaired; heart infusion; hemag... |
| immun | immune, immunity, immunization |
| RAPD | Relative Afferent Pupillary Defect |
| relative sensitivity | The sensitivity of a medical screening test as determined by comparison with the same type of test; e.g., sensitivity of a new serological test relative to sensitivity of an established serological test. (05 Mar 2000) |
|---|---|
| relative specificity | The specificity of a medical screening test as determined by comparison with the same type of test (e.g., specificity of a new serological test relative to specificity of an established serological test). (05 Mar 2000) |
| relative value scales | Coded listings of physician or other professional services using units that indicate the relative value of the various services they perform. They take into account time, skill, and overhead cost required for each service, but generally do not consider the relative cost-effectiveness. Appropriate conversion factors can be used to translate the abstract units of the relative value scales into dollar fees for each service based on work expended, practice costs, and training costs. (12 Dec 1998) |
| relative viscosity | The ratio of the viscosity of a solution or dispersion to the viscosity of the solvent or continuous phase. (05 Mar 2000) |
| 5-year relative survival rate | <statistics> The likelihood that a patient will not die from causes associated with his or her cancer for at least 5 years after diagnosis. This is the standard many professionals use when determining someone a survivor of cancer. (16 Dec 1997) |
| acquired immunity | <immunology> A form of cellular defense which identifies certain foreign substances (antigens) as harmful to the body. For this reason, the body can acquire resistance to a particular foreign agent. These foreign agents are then attacked by sensitised T lymphocytes (cellular immunity). White blood cells, plasma cells, B lymphocytes and other specialised immune system cells act in concert with T lymphocytes to produce antibodies (humoral immunity) that attach to the antigen directing T-cells to attack. Antibodies also stimulate the release of special chemical mediators in the blood (for example complement, interferon) that further enhance antigen destruction. (13 Nov 1997) |
| active immunity | <immunology> An organisms resistance to disease or infection, developed because the organisms immune system has produced antibodies after an infection or innoculation. (06 May 1997) |
| adoptive immunity | <immunology> Immunity to disease or infection conferred on a previously non-immune individual by transferring lymphocytes from a previously immune individual to the non-immune individual. (15 Jan 1998) |
| allograft immunity | <immunology> The recipient's immune system rejects tissue grafted from a genetically dissimilar donor (of the same species) and stages an immune attack against it. (09 Oct 1997) |
| antiviral immunity | Immunity resulting from virus infection, either naturally acquired or produced by intentional vaccination; compared to some bacterial immunity's, it is of relatively long duration, but this may be the result of infection-immunity rather than being peculiar to virus infection per se, since it occurs also in bacterial immunity after infections such as typhoid fever. (05 Mar 2000) |
| artificial active immunity | See: acquired immunity. (05 Mar 2000) |
| artificial passive immunity | See: acquired immunity. (05 Mar 2000) |
| bacteriophage immunity | The state induced in a bacterium by lysogenization, the lysogenic bacterium being insusceptible to further lysogenization or to a lytic cycle by a superinfecting bacteriophage, in contradistinction to bacteriophage resistance. (05 Mar 2000) |
| general immunity | Immunity associated with widely diffused mechanisms that tend to protect the body as a whole, as compared with local immunity. (05 Mar 2000) |
| maternal immunity | <epidemiology> Immunity for a neonate provided by IgG antibody generated by a mother and passed across the placenta to the unborn offspring. This provides short lived protection (with a typical half life of 3-6 months) to the neonate. Also known as immunity. (05 Dec 1998) |